Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo + Chemoimmunotherapy (CIT)	201
Overall Study	STARTED	Ibrutinib + CIT	202
Overall Study	Safety Analysis Set	Placebo + Chemoimmunotherapy (CIT)	199
Overall Study	Safety Analysis Set	Ibrutinib + CIT	201
Overall Study	Participants With Marginal Zone Lymphoma (MZL)	Placebo + Chemoimmunotherapy (CIT)	28
Overall Study	Participants With Marginal Zone Lymphoma (MZL)	Ibrutinib + CIT	28
Overall Study	Participants With Follicular Lymphoma (FL)	Placebo + Chemoimmunotherapy (CIT)	173
Overall Study	Participants With Follicular Lymphoma (FL)	Ibrutinib + CIT	174
Overall Study	COMPLETED	Placebo + Chemoimmunotherapy (CIT)	61
Overall Study	COMPLETED	Ibrutinib + CIT	65
Overall Study	NOT COMPLETED	Placebo + Chemoimmunotherapy (CIT)	140
Overall Study	NOT COMPLETED	Ibrutinib + CIT	137

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01974440/flow